Overview

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough

Status:
Not yet recruiting

Trial end date:
2024-09-24

Target enrollment:

Participant gender:

Summary

This Phase IIa, multicenter, randomized, double-blind, placebo-controlled, crossover study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamic (PD) effects of GDC-6599 compared with placebo in patients with a history of chronic cough.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Mannitol